18 results on '"Da Silva I"'
Search Results
2. 850P A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma
3. 798P NeoTrio – Optimal neoadjuvant (NAT) sequencing of anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis
4. 824P Patterns of response/progression and management following progressive disease (PD) with anti-PD-(L)1 (PD(L)1) in patients (pts) with advanced Merkel cell carcinoma (MCC)
5. 1662MO Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo)
6. LBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
7. 1106P NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma
8. 1094P NeoRisk: Neoadjuvant immunotherapy (NeoIT) recurrence risk assessment tool
9. 1088P Molecular profiling and matched targeted therapy for patients with advanced melanoma: Results from part I of the MatchMEL study
10. 133P Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III melanoma patients (pts) (NeoPele): Analysis of the peripheral immune profile correlated to pathological response
11. 72MO Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effectively than when given sequentially or with anti-PD-1 alone
12. 153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)
13. 1042P Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)
14. 545P Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
15. 1106P Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
16. 1106P International experience of ipilimumab and nivolumab in patients with advanced melanoma
17. Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts)
18. 1327P - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.